Jur-Shan Cheng, Kai-Feng Sung, Chi-Huan Wu, Chung-Wei Su, Cheng-Jen Chen, Cheng-Yu Lin, Tsung-Hsing Chen, Wei-Ting Chen, Wei-Pin Lin, Yi-Chung Hsieh, Jennifer Tai, Ya-Ting Cheng, Ming-Ling Chang
{"title":"Characteristic geoepidemiology and phenotype of autoimmune hepatitis: an 8-year population-based study in Taiwan.","authors":"Jur-Shan Cheng, Kai-Feng Sung, Chi-Huan Wu, Chung-Wei Su, Cheng-Jen Chen, Cheng-Yu Lin, Tsung-Hsing Chen, Wei-Ting Chen, Wei-Pin Lin, Yi-Chung Hsieh, Jennifer Tai, Ya-Ting Cheng, Ming-Ling Chang","doi":"10.1007/s12072-026-11161-w","DOIUrl":"https://doi.org/10.1007/s12072-026-11161-w","url":null,"abstract":"<p><strong>Background/aims: </strong>Data on the geoepidemiology and phenotype of autoimmune hepatitis (AIH) among individuals in Asia are limited.</p><p><strong>Methods: </strong>AIH patients were identified from the Taiwan National Health Insurance administrative database (n=24,867,461) with the ICD-10 CM code K75.4.</p><p><strong>Results: </strong>A total of 8909 AIH patients (females, n=6018) were included. The average age- and sex-adjusted prevalence (2016-2023) and incidence rates (2017-2023) were 20.505 per 100,000 population and 4.739 per 100,000 population per year, respectively. The overall annual percentage changes for prevalence and incidence were 25.56% (p<0.0001) and 4.85% (p<0.0001), respectively. Compared with AIH patients in southern Taiwan, AIH patients in northern Taiwan accounted for the majority (72.70%) and were younger at diagnosis (54.17 vs. 55.62 years, p=0.0011). The 8-year liver cirrhosis (LC), hepatocellular carcinoma (HCC), liver transplantation (LT), mortality and LT-free mortality cumulative incidence rates (CIRs) were 19.21%, 3.78%, 1.48%, 21.12% and 20.93%, respectively. The 8-year CIRs for hypertension, hyperlipidemia and diabetes were 44.77%, 46.84%, and 32.24%, respectively, and these diseases were the most common extrahepatic diseases. Lower hepatic and cardiometabolic complications and mortality but higher autoimmune complication CIRs were detected in northern than in southern Taiwan AIH patients. Higher hepatic and autoimmune complications but lower cardiometabolic complications and mortality CIRs were detected in female than in male AIH patients. Sex, age, residency, income, hepatic complications, diabetes and hyperlipidemia were associated with LC; sex, age, LC, ascites and diabetes were associated with HCC; and sex, age, residency, income, diabetes, hepatic complications, hyperlipidemia, systemic lupus erythematosus, thyroid diseases, systemic sclerosis and non-HCC cancers were associated with LT-free mortality.</p><p><strong>Conclusion: </strong>In Taiwan, the prevalence and incidence rates of AIH have increased over time. Care tailored to the patient's sex, age, residency, income and different complications is needed to improve outcomes.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":7.8,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149136394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Exploratory analysis of transcriptionally active HBV-host chimeric transcript burden in patients with increasing HBsAg during long-term antiviral therapy.","authors":"Luqi Tang, Bingqiong Wang, Yameng Sun, Shuyan Chen, Guiwen Guan, Jialing Zhou, Tongtong Meng, Wentao Tan, Shuai Xia, Xiaojuan Ou, Jidong Jia, Xiaoning Wu, Hong You","doi":"10.1007/s12072-026-11154-9","DOIUrl":"https://doi.org/10.1007/s12072-026-11154-9","url":null,"abstract":"<p><strong>Background and aims: </strong>The longitudinal relationship between transcriptionally active hepatitis B virus (HBV) integration dynamics and serum hepatitis B surface antigen (HBsAg) during long-term antiviral therapy remains unclear.</p><p><strong>Methods: </strong>Patients with HBV-related fibrosis/cirrhosis who underwent at least one liver biopsy at baseline, week 78, or week 260 were enrolled. HBsAg increase was defined as either a ≥5% increase from baseline to week 208 or at least two ≥5% increases between consecutive available visits. A subset of 10 patients with serial liver RNA sequencing underwent integrated clinical, transcriptomic, and histopathological analyses. HBV-host chimeric transcripts were identified using ChimericSeq and verified by BLAST, and intrahepatic HBsAg was assessed by immunohistochemistry.</p><p><strong>Results: </strong>Overall, 31.8% (99/311) of patients met the criteria for HBsAg increase, while others were classified into the stable/decrease group. Lower baseline HBsAg and higher histologic activity index (HAI) were independently associated with HBsAg increase (both p < 0.05). In the serial-biopsy subset (n = 10), patients in the HBsAg increase group (4/4) showed increased HBV-host chimeric transcript burden at week 260 versus week 78, whereas the six patients in the stable/decrease group showed stable or reduced burden. Intrahepatic HBsAg immunohistochemistry showed persistent clustered cytoplasmic positivity, with transcriptomic analysis indicating downregulation of multiple immune-related pathways in the HBsAg increase group.</p><p><strong>Conclusion: </strong>About 31.8% of patients had HBsAg increase during antiviral therapy. Baseline HBsAg and HAI were associated with HBsAg increase during antiviral therapy. In the exploratory serial-biopsy subset, patients with HBsAg increase tended to exhibit an increase in transcriptionally active HBV-host chimeric transcript burden and persistent clustered cytoplasmic HBsAg positivity.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":7.8,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149136361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Shumin Li, Ziyi Yang, Xin Huang, Mingwei Zhong, Shibo Lin, Teng Liu, Han Zhao, Shaozhuang Liu, Shigang Zhao, Zi-Jiang Chen
{"title":"A simple clinical model for predicting multiple liver histologic injuries in obese individuals undergoing bariatric surgery.","authors":"Shumin Li, Ziyi Yang, Xin Huang, Mingwei Zhong, Shibo Lin, Teng Liu, Han Zhao, Shaozhuang Liu, Shigang Zhao, Zi-Jiang Chen","doi":"10.1007/s12072-026-11159-4","DOIUrl":"https://doi.org/10.1007/s12072-026-11159-4","url":null,"abstract":"<p><strong>Background: </strong>Metabolic dysfunction-associated steatotic liver disease (MASLD) is common among obese individuals undergoing bariatric surgery, but liver biopsy is invasive and existing noninvasive tools generally assess single histologic features. We aimed to develop and externally validate a simple framework for predicting multiple liver histologic injuries.</p><p><strong>Methods: </strong>We included 909 obese individuals undergoing sleeve gastrectomy with intraoperative liver biopsy in the training cohort and 186 temporally separated patients in the internal test cohort. Six separate outcome-specific binary classification models were developed, one for each histologic outcome: steatosis, hepatocyte ballooning, significant fibrosis, metabolic dysfunction-associated steatohepatitis (MASH), NAS ≥5, and at-risk MASH. Multiple machine-learning algorithms were evaluated, and the best-performing algorithm was selected for each outcome. A simplified three-variable TabPFN framework using alanine aminotransferase, homeostasis model assessment of insulin resistance, and peripheral monocyte ratio was developed, with one binary model for each outcome. External validation included two biopsy-confirmed cohorts (n = 103 and 217) and the U.S. NHANES cohort (n = 4,299) using elastography-based assessments.</p><p><strong>Results: </strong>The models demonstrated good discrimination for multiple histologic liver injuries in the test cohort, with ROC-AUCs ranging from 0.73 to 0.86 across outcomes. The simplified three-variable framework showed consistent external performance, achieving ROC-AUCs of 0.84 for ballooning, 0.86 for steatosis, 0.79 for significant fibrosis, and 0.75 for MASH. The framework demonstrated generalizability in the NHANES population.</p><p><strong>Conclusions: </strong>This externally validated framework may support noninvasive identification of multiple liver histologic injuries and perioperative liver risk stratification in individuals undergoing bariatric surgery, thereby improving the clinical accessibility of liver pathology assessment.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":7.8,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149136450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Teng-Rui Cao, Li-Juan Wu, Xing-Hua Yang, Ning-Fei Fan, Jie Ding, Miao Gong, Xu-Man Feng, Yi-Han Li, Yu-Xiang Yan
{"title":"Plasma proteomic signatures of biological aging and metabolic dysfunction-associated steatotic liver disease risk: a prospective cohort study.","authors":"Teng-Rui Cao, Li-Juan Wu, Xing-Hua Yang, Ning-Fei Fan, Jie Ding, Miao Gong, Xu-Man Feng, Yi-Han Li, Yu-Xiang Yan","doi":"10.1007/s12072-026-11155-8","DOIUrl":"https://doi.org/10.1007/s12072-026-11155-8","url":null,"abstract":"<p><strong>Background: </strong>Biological aging is associated with incident metabolic dysfunction-associated steatotic liver disease (MASLD), but the underlying proteomic mechanisms remain largely unknown. This study aimed to systematically characterize the plasma proteomic landscape and identify specific biomarkers that mediate the aging-MASLD axis.</p><p><strong>Methods: </strong>We analyzed the associations between four multi-dimensional biological aging indicators (telomere length, frailty index, Klemera-Doubal method biological age, and phenotypic age), 2911 plasma proteins, and incident MASLD among 52,131 UK Biobank participants. A rigorous two-stage analytical pipeline, integrating multivariable linear and elastic net regression, was applied to screen robust aging-related proteins. Cox proportional hazard regression models and mediation analyses were employed to assess their roles in MASLD risk, followed by comprehensive tissue and functional enrichment analyses to elucidate underlying biological mechanisms.</p><p><strong>Results: </strong>During a median follow-up of 13.60 years, 762 participants developed MASLD. All biological aging indicators were significantly linked to MASLD incidence. We identified distinct proteomic signatures for these biological aging indicators. Furthermore, multiple proteins significantly mediated the corresponding association, explaining 0.5 to 50.7% of the risk. Notably, 769 unique mediators were identified, anchored by a core signature of five shared proteins (AXL, CCL19, CPM, REN, and TNFRSF11B) across all four indicators. Enrichment analyses revealed a multi-organ origin (predominantly lung, adipose tissue, and arteries), highlighting the dominance of immune-inflammatory pathways.</p><p><strong>Conclusions: </strong>Plasma proteins partially mediate the increased MASLD risk driven by biological aging. These findings underscore the roles of systemic immune-inflammatory signaling, providing biomarkers for early risk stratification and potential novel therapeutic targets for aging-associated hepatic pathology.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":7.8,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149127273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Wouter Robaeys, Leen Jm Heyens, Liesbeth Bruckers, Joris Penders, Mathieu Struyve, Ger H Koek, Sven Ma Francque, Geert Kmm Robaeys
{"title":"Randomised trial of lifestyle interventions for improving metabolic dysfunction-associated steatotic liver disease.","authors":"Wouter Robaeys, Leen Jm Heyens, Liesbeth Bruckers, Joris Penders, Mathieu Struyve, Ger H Koek, Sven Ma Francque, Geert Kmm Robaeys","doi":"10.1007/s12072-026-11153-w","DOIUrl":"https://doi.org/10.1007/s12072-026-11153-w","url":null,"abstract":"<p><strong>Background and aims: </strong>Lifestyle modification is the cornerstone of treatment for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). To date, no published randomised controlled trials (RCTs) have provided a direct, head-to-head comparison between mobile (m)-health and structured, human-led dietitian coaching in the management of MASLD.</p><p><strong>Methods: </strong>In a single-centre, 12-month RCT, participants (n=297) were randomised into three arms: (1) minimal intervention therapy (MIT) (n=102), (2) lifestyle coaching (n=97), and 3) m-health (n=98). Steatosis was measured using the controlled-attenuation parameter (CAP™), steatohepatitis by aspartate aminotransferase (AST), and fibrosis by vibration-controlled transient elastography (VCTE™).</p><p><strong>Results: </strong>Across all three study arms, an equally (p=0.998) significant reduction in CAP™ was observed. The mean CAP™ change was -23.94 dB/m (95% CI [- 36.70; -11.17], p<0.001) for the MIT group, -23.66 dB/m (95% CI [- 36.08;-11.23], p<0.001) for the lifestyle coaching group, and -21.96 dB/m (95% CI: [- 35.77;-8.15], p=0.002) for the m-health group. Over the 12-month period, guidance via m-health resulted in a significant decrease in mean serum AST levels (- 2.81 U/L (95% CI [- 5.06;-0.57], p=0.014). None of the intervention methods had a significant effect on fibrosis.</p><p><strong>Conclusions: </strong>This study shows that all three lifestyle-guidance modalities produced comparable, significant reductions in liver steatosis over 12 months, with no significant differences between groups and no observed changes in liver stiffness. These findings support m-health as a feasible, scalable alternative in MASLD management, though multi-centre validation is warranted to confirm these outcomes. TRAIL REGISTRATIONS: (clinicaltrials.gov NCT05792488).</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":7.8,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149108816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hepatology InternationalPub Date : 2026-10-01Epub Date: 2026-09-24DOI: 10.1007/s12072-026-11136-x
Anand V Kulkarni, Ashok Choudhury, Vinod Arora, Abdul Kadir Dokmeci, Abraham Koshy, Ahmet Gurakar, Ajay Duseja, Akash Roy, Akash Shukla, Aleksander Krag, Alfred Wei Chieh Kow, Ananta Shrestha, Apichat Kaewdech, Ashish Goel, Ashish Kumar, Ashwani K Singal, Aung Hlaing Bwa, Chanunta Hongthanakorn, Cosmas Rinaldi Adithya Lesmana, Daniel Huang, Darrell Crawford, Debbie Shawcross, Deniz Balchi, Dhiraj Agrawal, Diana A Payawal, Do Seon Song, Dong Joon Kim, Fernando Bessone, George K Lau, Giacomo Germani, Girish Kumar Pati, Grace L Su, Guan-Huei Lee, Gupse Adali, Gyongyi Szabo, Hasmik Ghazinian, Jacob George, James Fung, Jasmohan Bajaj, P Javed, Jidong Jia, Jimmy Che-To Lai, Jin Jun Chen, Jonel Trebicka, Jun Li, Kavish Patidar, Kemal Fariz Kalista, Ken Liu, Kessarin Thanapirom, Lai Wei, M Golam Azam, Madhumita Premkumar, Madunil Niriella, Manasa Alla, Mangesh Pagadala, Manoj Kumar, Manuel Mendizabal, Mario Guimaraes Pessoa, Mark Dhinesh Muthiah, Masao Omata, Mazen Noureddin, Md Fazal Karim, Mithun Sharma, Mohamed Alboraie, Mohamed Elbasiony, Murat Harputluoglu, Narendra Singh Choudhary, Nazia Selzner, Necati Ormeci, Nelia Hernandez, Nipun Verma, Paolo Angeli, Phunchai Charatcharoenwitthaya, Prabir Maji, Pravin Rathi, R K Dhiman, Rahul Kumar, Rakhi Maiwall, Ramazan Idilman, Richard Moreau, Rino A Gani, Rosmawati Mohamed, S S Hamid, Sanjeev Sachdeva, Senamjit Kaur, Shahinul Alam, Soe Thiha Maung, Soek-Siam Tan, T R Sowmya, K C Sudhamshu, Sumana Ramachandra, Sunil Kumar Dadhich, Sunil Taneja, Suprabhat Giri, Surender Singh, Tao Chen, Tarana Gupta, Tushar Madke, V M Dayal, Venishetty Shantan, Viniyendra Pamecha, Wong Yu Jun, Xiaolong Qi, Yoon Jun Kim, Zaigham Abbas, Zobair M Younossi, Shiv Kumar Sarin
{"title":"The Global ACLF Consensus : the 'Istanbul Document'.","authors":"Anand V Kulkarni, Ashok Choudhury, Vinod Arora, Abdul Kadir Dokmeci, Abraham Koshy, Ahmet Gurakar, Ajay Duseja, Akash Roy, Akash Shukla, Aleksander Krag, Alfred Wei Chieh Kow, Ananta Shrestha, Apichat Kaewdech, Ashish Goel, Ashish Kumar, Ashwani K Singal, Aung Hlaing Bwa, Chanunta Hongthanakorn, Cosmas Rinaldi Adithya Lesmana, Daniel Huang, Darrell Crawford, Debbie Shawcross, Deniz Balchi, Dhiraj Agrawal, Diana A Payawal, Do Seon Song, Dong Joon Kim, Fernando Bessone, George K Lau, Giacomo Germani, Girish Kumar Pati, Grace L Su, Guan-Huei Lee, Gupse Adali, Gyongyi Szabo, Hasmik Ghazinian, Jacob George, James Fung, Jasmohan Bajaj, P Javed, Jidong Jia, Jimmy Che-To Lai, Jin Jun Chen, Jonel Trebicka, Jun Li, Kavish Patidar, Kemal Fariz Kalista, Ken Liu, Kessarin Thanapirom, Lai Wei, M Golam Azam, Madhumita Premkumar, Madunil Niriella, Manasa Alla, Mangesh Pagadala, Manoj Kumar, Manuel Mendizabal, Mario Guimaraes Pessoa, Mark Dhinesh Muthiah, Masao Omata, Mazen Noureddin, Md Fazal Karim, Mithun Sharma, Mohamed Alboraie, Mohamed Elbasiony, Murat Harputluoglu, Narendra Singh Choudhary, Nazia Selzner, Necati Ormeci, Nelia Hernandez, Nipun Verma, Paolo Angeli, Phunchai Charatcharoenwitthaya, Prabir Maji, Pravin Rathi, R K Dhiman, Rahul Kumar, Rakhi Maiwall, Ramazan Idilman, Richard Moreau, Rino A Gani, Rosmawati Mohamed, S S Hamid, Sanjeev Sachdeva, Senamjit Kaur, Shahinul Alam, Soe Thiha Maung, Soek-Siam Tan, T R Sowmya, K C Sudhamshu, Sumana Ramachandra, Sunil Kumar Dadhich, Sunil Taneja, Suprabhat Giri, Surender Singh, Tao Chen, Tarana Gupta, Tushar Madke, V M Dayal, Venishetty Shantan, Viniyendra Pamecha, Wong Yu Jun, Xiaolong Qi, Yoon Jun Kim, Zaigham Abbas, Zobair M Younossi, Shiv Kumar Sarin","doi":"10.1007/s12072-026-11136-x","DOIUrl":"10.1007/s12072-026-11136-x","url":null,"abstract":"<p><p>The Kyoto Consensus introduced a key conceptual shift in characterizing acute-on-chronic liver failure (ACLF) patients into Type-A and Type-B phenotypes. A day-long meeting was convened at Istanbul during APASL 2026 to assess the real-world applicability of Type-A and Type-B ACLF across continents. The objective was that physicians could recognize ACLF as a unified disease entity, and quality research and new therapeutic options with defined end-points could be undertaken. Data from APASL ACLF Research Consortium (AARC), EASL-CLIF and NACSELD were assessed and discussed in detail. While the applicability of Type-A and Type-B varied across cohorts, the definition required to be appended. The experts unanimously agreed that 'liver failure' as identified by serum bilirubin of ≥ 5 mg/dl and INR ≥ 1.5 should be the 'core' for both Type-A and Type-B ACLF. Type-A ACLF is considered when \"a patient with compensated advanced chronic liver disease or compensated cirrhosis presents with index decompensation as liver failure followed by development of ascites and/or hepatic encephalopathy within 4 weeks.\" Type-B ACLF is considered when \"a patient with prior or concurrent decompensated cirrhosis presents with acute decompensation as liver failure accompanied by one or more extrahepatic organ failures.\" New definitions of organ dysfunction and failure, as well as endpoints for clinical trials, were also deliberated and finalized. The \"Istanbul Report\", presents a milestone evidence based consensus document carrying harmonization of various aspects of ACLF, incorporating current evidence, critically analyzed unanimous recommendations, and key areas for future studies.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1281-1294"},"PeriodicalIF":7.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149038226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hepatology InternationalPub Date : 2026-10-01Epub Date: 2026-02-06DOI: 10.1007/s12072-026-11036-0
Sohana Memon, Gaaitri Lohano, Govinda Lohano
{"title":"Letter to the Editor: \"Critical appraisal of MASLD subtypes and pregnancy outcome associations in a nationwide cohort\".","authors":"Sohana Memon, Gaaitri Lohano, Govinda Lohano","doi":"10.1007/s12072-026-11036-0","DOIUrl":"10.1007/s12072-026-11036-0","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1526-1527"},"PeriodicalIF":7.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146131604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hepatology InternationalPub Date : 2026-10-01Epub Date: 2026-02-05DOI: 10.1007/s12072-026-11033-3
Young Mi Jung, Geum Joon Cho, Won Kim
{"title":"Response to letter to editor: toward more precise and generalizable evidence on MASLD and pregnancy risks.","authors":"Young Mi Jung, Geum Joon Cho, Won Kim","doi":"10.1007/s12072-026-11033-3","DOIUrl":"10.1007/s12072-026-11033-3","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1524-1525"},"PeriodicalIF":7.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146124800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"AGEX: a comprehensive database of clinically relevant genetic variants associated with Alagille syndrome across diverse populations.","authors":"Priya Sharma, Vishnu Prasad, Bhanu Teja Korra, Rohan Grotra, Rohan Malik, Rahul Kumar, Deepti Abbey","doi":"10.1007/s12072-026-11074-8","DOIUrl":"10.1007/s12072-026-11074-8","url":null,"abstract":"<p><strong>Background: </strong>Alagille syndrome (ALGS) is a rare multisystem disorder primarily caused by pathogenic variants in JAG1 and NOTCH2. Although its genetic basis is well established, existing variant repositories often lack comprehensive clinical annotation, sufficient ethnic representation, and open accessibility. These limitations reduce their translational relevance and hinder genotype-phenotype correlation and evidence-based molecular diagnosis. To address this gap, we developed AGEX (Alagille Genetics Exploration Database), a curated, open-access resource integrating genetic variants with phenotype and population frequency data.</p><p><strong>Methods: </strong>AGEX ( http://agexbase.iitd.ac.in ) was constructed through a systematic literature review from 1999-2025, supplemented with unpublished case reports from Indian ALGS patients. Variants were curated and classified according to ACMG/AMP guidelines, with pathogenicity predictions derived from multiple in silico tools. Population allele frequency data were integrated from gnomAD, All of Us, and IndiGenome databases. Domain-level mutation mapping was performed to assess variant distribution across functional protein regions. Additionally, a prototype ALGS Severity Tier Calculator was developed to integrate genotype and phenotype parameters for semi-quantitative clinical stratification.</p><p><strong>Results: </strong>AGEX compiles 260 variants, including 231 in JAG1 and 29 in NOTCH2, reported across 20 global populations. Four previously unreported variants were identified. Domain-level analysis revealed recurrent clustering of mutations within the DSL and EGF-like domains of JAG1, emphasizing their importance in Notch signaling. The database provides an interactive interface enabling variant browsing, phenotype-linked queries, and population-level analyses, along with a prototype severity scoring framework.</p><p><strong>Conclusion: </strong>AGEX represents the first dedicated integrative database for ALGS, enabling variant browsing, population-specific analyses, and phenotype-linked searches. While further longitudinal clinical validation is required, AGEX represents the first dedicated, integrative database for ALGS. By centralizing variant and clinical data, AGEX aims to accelerate diagnosis, improve patient stratification, and facilitate precision medicine strategies targeting Notch pathway dysregulation, serving as a scalable model for other rare disorder genomics.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1409-1419"},"PeriodicalIF":7.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147493395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}